BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Breaking News: Try BioWorld for free for two weeks
See today's BioWorld Science
Home
» Invivyd selects VYD-222 to advance as monoclonal antibody therapeutic option for COVID-19
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full article
sign up for free
or
sign in
.
Infection
Invivyd selects VYD-222 to advance as monoclonal antibody therapeutic option for COVID-19
March 7, 2023
No Comments
Invivyd Inc. has selected VYD-222 to advance into the clinic as a novel monoclonal antibody therapeutic option for COVID-19. VYD-222...
BioWorld Science
Immune
Infection
Coronavirus
Monoclonal antibody